Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.

Autor: Motzer, Robert J.1 (AUTHOR) motzerr@mskcc.org, Escudier, Bernard2 (AUTHOR), George, Saby3 (AUTHOR), Hammers, Hans J.4 (AUTHOR), Srinivas, Sandhya5 (AUTHOR), Tykodi, Scott S.6 (AUTHOR), Sosman, Jeffrey A.7 (AUTHOR), Plimack, Elizabeth R.8 (AUTHOR), Procopio, Giuseppe9 (AUTHOR), McDermott, David F.10 (AUTHOR), Castellano, Daniel11 (AUTHOR), Choueiri, Toni K.12 (AUTHOR), Donskov, Frede13 (AUTHOR), Gurney, Howard14 (AUTHOR), Oudard, Stéphane15 (AUTHOR), Richardet, Martin16 (AUTHOR), Peltola, Katriina17 (AUTHOR), Alva, Ajjai S.18 (AUTHOR), Carducci, Michael19 (AUTHOR), Wagstaff, John20 (AUTHOR)
Zdroj: Cancer (0008543X). Sep2020, Vol. 126 Issue 18, p4156-4167. 12p.
Databáze: Academic Search Ultimate
Externí odkaz: